DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR RESCRIPTOR

« Back to Dashboard

Clinical Trials for Rescriptor

Trial ID	Title	Status	Sponsor	Phase	Summary
NCT00002210	A Study of Delavirdine Mesylate in Combination With Other Anti-HIV Drugs in HIV-Infected Children and Babies	Completed	Pharmacia and Upjohn	Phase 2	The purpose of this study is to see if it is safe and effective to give delavirdine mesylate (Rescriptor) plus two nucleoside reverse transcriptase inhibitors (NRTIs) to HIV-infected children and babies. This study also examines how the body processes Rescriptor when taken with 2 NRTIs.
NCT00002211	Safety and Effectiveness of Giving Combinations of Three or Four Anti-HIV Drugs to HIV-Infected Patients	Completed	Pharmacia and Upjohn	N/A	The purpose of this study is to see if it is safe and effective to give combinations of three or four anti-HIV drugs to HIV-infected patients. The drugs used in this study are delavirdine (DLV), nelfinavir (NLF), didanosine (ddI), and stavudine (d4T).
NCT00002400	A Study of Two Anti-HIV Drug Combinations in HIV-Infected Patients	Completed	Pharmacia and Upjohn	N/A	The purpose of this study is to compare the safety and effectiveness of giving HIV-infected patients delavirdine (DLV) plus zidovudine (ZDV) plus 2 doses of indinavir (IDV) or ZDV plus IDV plus lamivudine (3TC). This study also examines how the body processes DLV when it is given in combination with other drugs.
NCT00002401	A Study of Delavirdine Used Together With Other Anti-HIV Drugs in HIV-Infected Patients	Completed	Pharmacia and Upjohn	N/A	The purpose of this study is to see if it is safe and effective to give delavirdine (DLV) in combination with two or three other drugs to HIV-infected patients. The drugs to be used in combination with DLV are zidovudine (ZDV), indinavir (IDV), and lamivudine (3TC).
NCT00002420	The Safety and Effectiveness of Didanosine Plus Stavudine Plus Delavirdine Mesylate Plus MKC-442 in HIV-Infected Patients Who Have Not Had Success With Protease Inhibitors	Terminated	Pharmacia and Upjohn	Phase 2	The purpose of this study is to see if it is safe and effective to give MKC-442, didanosine (ddI), stavudine (d4T), and delavirdine (DLV) to HIV-positive patients.

Clinical Trial Conditions for Rescriptor

Condition Name

Condition Name for Rescriptor
Intervention	Trials
HIV Infections	6
HIV-1 Infection	1

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Rescriptor
Intervention	Trials
HIV Infections	7
Acquired Immunodeficiency Syndrome	1

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Rescriptor

Trials by Country

Trials by Country for Rescriptor
Location	Trials
United States	9

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Rescriptor
Location	Trials
New Jersey	4
California	2
New York	1
Missouri	1
Maryland	1

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Rescriptor

Clinical Trial Phase

Clinical Trial Phase for Rescriptor
Clinical Trial Phase	Trials
Phase 4	1
Phase 2/Phase 3	1
Phase 2	2

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Rescriptor
Clinical Trial Phase	Trials
Completed	6
Terminated	1

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Rescriptor

Sponsor Name

Sponsor Name for Rescriptor
Sponsor	Trials
Pharmacia and Upjohn	5
University of California, San Diego	1
National Institutes of Health (NIH)	1

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Rescriptor
Sponsor	Trials
Industry	8
NIH	2
Other	1

Export unavailable in trial.
Subscribe for complete access.